Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005203947
Thu, 31.10.2024
BRAIN Biotech AG
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology
Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise
BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees plus additional royalties in exchange for granti [ … ]
Thu, 31.10.2024
BRAIN Biotech AG
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
BRAIN Biotech AG signs exclusive pharma licensing ag [ … ]
Thu, 03.10.2024
BRAIN Biotech AG
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Superv [ … ]
Fri, 20.09.2024
BRAIN Biotech AG
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech
Immediate upfront payment of EUR 18.41 million
Royalty monetization of an investigational compound, deucrictiban [ … ]
Fri, 20.09.2024
BRAIN Biotech AG
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech
Immediate upfront payment of EUR 18.41 million
Royalty monetization of an investigational compound, deucrictiban [ … ]
Fri, 20.09.2024
BRAIN Biotech AG
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
BRAIN Biotech AG concludes royalty monetization d [ … ]
Fri, 20.09.2024
BRAIN Biotech AG
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
BRAIN Biotech AG concludes royalty monetization d [ … ]
Thu, 29.08.2024
BRAIN Biotech AG
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
Cash on-hand at € 13 million
Significantly improved operating cash-flow in the 9M
Forecasting a sequentially strong BioProducts quarter in Q4 FY 23/24
August 29, 2024, Zwingenberg/Germany – BRAI [ … ]
Wed, 29.05.2024
BRAIN Biotech AG
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
Zwingenberg and Greifswald, May 29, 2024 – BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as Senior Business Development Director Enzymes as of June 1st, 2024. De Vries will continue [ … ]
Tue, 28.05.2024
BRAIN Biotech AG
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
Major milestone payment from pharma-project of € 1.5 million received
BioProducts business growth accelerated in Q2, further acceleration expected throughout H2
On-track to meet fiscal year end targets
Significantly strengthened cash position
Zwing [ … ]